Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top M&A Of 2016: Cast Your Vote!

Executive Summary

It's time once again for In Vivo's Deal of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

In Vivo's Top M&A Of 2016 – The Nominees Are

A Big Year For NASH: Allergan PLC built anon-alcoholic steatohepatitis franchise overnight in mid-September, acquiring Tobira Therapeutics Inc. for $1.7bn and Akarna Therapeutics Inc. for $50m. In April, Gilead Sciences Inc. paid $400m up front plus earn-outs for its fourth NASH project, Nimbus Apollo Inc. and its Phase II-ready ACC inhibitor for NASH. (Also see "Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn" - Scrip, 21 Sep, 2016.) (Also see "Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease" - Scrip, 5 Apr, 2016.) [See Deal][See Deal]

LabCorp Strengthens Women's Health Offering With Sequenom Buy: In July, LabCorp of America announced its intent to acquire noninvasive prenatal testing specialist Sequenom Inc. in an all-cash deal. The transaction enables LabCorp to broaden its test offerings in women's health and expand its geographic reach, among other things. (Also see "LabCorp Broadens Women's Health Offering With Sequenom Buy" - Medtech Insight, 27 Jul, 2016.) [See Deal]

Pfizer Prevails In Medivation Bidding War: In the biggest pharma M&A deal of the year to date, Pfizer Inc. bested multiple competitors with a $14bn in August bid for prostate cancer drug developer Medivation Inc., showing just how far big pharmas are willing to go to compete in oncology. (Also see "Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?" - Scrip, 23 Aug, 2016.) [See Deal]

Abbott Buys St. Jude For $25bn: This April deal was the biggest medtech acquisition of the year, and created huge consolidation in the cardiovascular device market. (Also see "Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal" - Medtech Insight, 28 Apr, 2016.) [See Deal]

QuintilesIMS: Big Merger In Big Data: CRO Quintiles Transnational Holdings Inc. merged with health care data giant IMS Health Inc. in May in a deal worth $9bn. QuintilesIMS will have a market cap close to $18bn, not to mention a huge head start in finding real-world evidence solutions for clients. (Also see "QuintilesIMS’ Chan On Real-World Evidence Hubs, Reverse Innovation" - Scrip, 11 Dec, 2016.)

CLICK HERE To Cast Your Vote For The Most Significant M&A Of 2016

CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016

CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016

Advertisement

Related Content

QuintilesIMS’ Chan On Real-World Evidence Hubs, Reverse Innovation
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
LabCorp Broadens Women's Health Offering With Sequenom Buy
Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal
Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097916

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel